公开(公告)号：US09101688B2

公开(公告)日：2015-08-11

申请号：US12198846

申请日：2008-08-26

Applicant: J. Maxwell Teets ,  Christopher Bare ,  Tara L. Schaneville

Inventor： J. Maxwell Teets ,  Christopher Bare ,  Tara L. Schaneville

IPC: A61F2/00 ,  A61K9/48 ,  A61K35/16 ,  A61K35/28 ,  A61L27/24 ,  A61K35/14 ,  A61K35/19 ,  A61L27/36

CPC classification number: A61L27/24 ,  A61K9/4866 ,  A61K35/14 ,  A61K35/16 ,  A61K35/19 ,  A61K35/28 ,  A61L27/3616 ,  A61L27/3654

Abstract: Methods and systems for delivering biological products to different surgical sites during surgery are described. The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers that are natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties of such films. The water soluble films may be processed into capsules, packets or other containers.

Abstract translation: 描述了在手术过程中将生物制品递送到不同手术部位的方法和系统。 生物制品被包封或包含在包含诸如胶原载体的载体的容纳系统中。 容纳系统可以由天然的，合成的或半合成的水溶性聚合物形成，提供成可制成或模制成各种形状和尺寸的膜，并且可以被操纵以赋予这种膜的特定性质。 水溶性薄膜可以加工成胶囊，包装或其它容器。

公开(公告)号：US08460227B2

公开(公告)日：2013-06-11

申请号：US12616081

申请日：2009-11-10

Applicant: Christopher Bare ,  David O. Shepard

Inventor： Christopher Bare ,  David O. Shepard

IPC: A61M37/00 ,  A61B19/00

CPC classification number: C07K14/54 ,  B01L3/5021

Abstract: Apparatus and methods for producing interleukin-1 receptor antagonist and/or other prophylatically or therapeutically effective protein. Blood is obtained from a patient with a conventional syringe and then introduced into dual luer lock centrifuge tube. The dual luer lock centrifuge tube is provided with beads that are coated with a silanized coating. The container is then incubated and centrifuged. Subsequent to the incubation and the centrifugation, the serum containing autologous therapeutically active protein, such as IL-1Ra, in the container is withdrawn through the luer lock of the container, and injected back into the patient.

Abstract translation: 用于产生白细胞介素-1受体拮抗剂和/或其它预防或治疗有效蛋白质的装置和方法。 使用常规注射器从患者获得血液，然后引入双路厄锁定离心管。 双路厄尔锁离心管配有涂有硅烷化涂层的珠子。 然后将容器温育并离心。 在孵育和离心之后，容器中含有自体治疗活性蛋白（例如IL-1Ra）的血清通过容器的鲁尔锁取出，并注射到患者体内。

公开(公告)号：US20090060975A1

公开(公告)日：2009-03-05

申请号：US12198846

申请日：2008-08-26

Applicant: J. Maxwell Teets ,  Christopher Bare ,  Tara L. Schaneville

Inventor： J. Maxwell Teets ,  Christopher Bare ,  Tara L. Schaneville

IPC: A61K9/48 ,  A61K47/26 ,  A61K47/36 ,  A61K35/16 ,  A61K9/10 ,  A61P41/00 ,  A61F2/02 ,  A61K35/28 ,  A61K35/14 ,  A61K47/30

CPC classification number: A61L27/24 ,  A61K9/4866 ,  A61K35/14 ,  A61K35/16 ,  A61K35/19 ,  A61K35/28 ,  A61L27/3616 ,  A61L27/3654

Abstract: Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers, either natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties (such as solubility or degradation rates according to a specific environment, for example) of such films. The water soluble films may be processed into capsules, packets or other containers.

Abstract translation: 在诸如骨髓抽吸物（BMA）等生物制品在手术期间向不同手术部位输送（例如关节镜手术）的方法和系统。 生物制品被包封或包含在包含诸如胶原载体的载体的容纳系统中。 容纳系统可以由天然的，合成的或半合成的水溶性聚合物形成，提供成可制成或模制成各种形状和尺寸的膜，并且可以被操纵以赋予特定性质（例如溶解度或降解速率 例如）到这种薄膜的特定环境中。 水溶性薄膜可以加工成胶囊，包装或其它容器。

公开(公告)号：US20050158699A1

公开(公告)日：2005-07-21

申请号：US10871705

申请日：2004-06-21

Applicant: Prakash Kadkade ,  Christopher Bare ,  Barbara Schnabel-Preikstas ,  Bin Yu

Inventor： Prakash Kadkade ,  Christopher Bare ,  Barbara Schnabel-Preikstas ,  Bin Yu

IPC: A01N1/02 ,  C12N5/04

CPC classification number: A01N1/0284 ,  A01N1/0221

Abstract: The present invention relates to methods for cryopreserving plant cells and to methods for recovering viable plant cells from long or short term cryopreservation. Plant cells to be cryopreserved can be grown in culture and pretreated with a solution containing an cryoprotective agent and, optionally, a stabilizer. Stabilizers are preferably membrane stabilizers such as ethylene inhibitors, oxygen radical scavengers and divalent cations. Cells can also be stabilized by subjecting the culture to a heat shock. Pretreated cells are acclimated to a reduced temperature and loaded with a cryoprotective agent such as DMSO, propylene glycol or polyethylene glycol. Loaded cells are incubated with a vitrification solution which, for example, comprises a solution with a high concentration of the cryoprotective agent. Vitrified cells retain less than about 20% water content and can be frozen at cryopreservation temperatures for long periods of time without significantly altering the genotypic or phenotypic character of the cells. Plant cells may also be cryopreserved by lyophilizing cells prior to exposure to a vitrification solution. The combination of lyophilization and vitrification removes about 80% to about 95% of the plant cell's water. Cells can be successfully cryopreserved for long periods of time and viably recovered. The invention also relates to methods for the recovery of viable plant cells from cryopreservation. Cells are thawed to about room temperature and incubated in medium containing a cryoprotective agent and a stabilizer. The cryoprotective agent is removed and the cells successfully incubated and recovered in liquid or semi-solid growth medium. The invention also relates to the cryopreserved cells and to viable plant cells which have been recovered from long or short term cryopreservation.

Abstract translation: 本发明涉及用于冷冻保存植物细胞的方法和从长期或短期冷冻保存中回收活的植物细胞的方法。 待冷冻保存的植物细胞可以在培养物中生长并用含有冷冻保护剂和任选的稳定剂的溶液预处理。 稳定剂优选为膜稳定剂，例如乙烯抑制剂，氧自由基清除剂和二价阳离子。 也可以通过使培养物受热休克来稳定细胞。 预处理的细胞适应于降低的温度，并加载冷冻保护剂如DMSO，丙二醇或聚乙二醇。 将加载的细胞与玻璃化溶液一起孵育，所述玻璃化溶液例如包含具有高浓度冷冻保护剂的溶液。 玻璃化细胞保留少于约20％的水含量，并且可以在冷冻保存温度下长时间冷冻，而不显着改变细胞的基因型或表型特征。 植物细胞也可以在暴露于玻璃化溶液之前由冻干细胞冷冻保存。 冻干和玻璃化的组合消除了植物细胞水的约80％至约95％。 细胞可以成功地冷冻保存长时间，有效地恢复。 本发明还涉及从冷冻保存中回收活的植物细胞的方法。 将细胞解冻至约室温，并在含有冷冻保护剂和稳定剂的培养基中孵育。 除去冷冻保护剂，并将细胞在液体或半固体生长培养基中成功培养和回收。 本发明还涉及冷冻保存的细胞和已经从长期或短期冷冻保存中回收的活的植物细胞。

公开(公告)号：US20100125236A1

公开(公告)日：2010-05-20

申请号：US12616081

申请日：2009-11-10

Applicant: Christopher Bare ,  David O. Shepard

Inventor： Christopher Bare ,  David O. Shepard

IPC: A61M1/36 ,  C12P1/00

CPC classification number: C07K14/54 ,  B01L3/5021

Abstract: Apparatus and methods for producing interleukin-1 receptor antagonist and/or other prophylatically or therapeutically effective protein. Blood is obtained from a patient with a conventional syringe and then introduced into dual luer lock centrifuge tube. The dual luer lock centrifuge tube is provided with beads that are coated with a silanized coating. The container is then incubated and centrifuged. Subsequent to the incubation and the centrifugation, the serum containing autologous therapeutically active protein, such as IL-1Ra, in the container is withdrawn through the luer lock of the container, and injected back into the patient.

Abstract translation: 用于产生白细胞介素-1受体拮抗剂和/或其它预防或治疗有效蛋白质的装置和方法。 使用常规注射器从患者获得血液，然后引入双路厄锁定离心管。 双路厄尔锁离心管配有涂有硅烷化涂层的珠子。 然后将容器温育并离心。 在孵育和离心之后，容器中含有自体治疗活性蛋白（例如IL-1Ra）的血清通过容器的鲁尔锁取出，并注射到患者体内。